258 related articles for article (PubMed ID: 32416592)
1. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Şentürk R; Wang Y; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1147():122131. PubMed ID: 32416592
[TBL] [Abstract][Full Text] [Related]
2. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Sparidans RW; Wang Y; Schinkel AH; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():167-172. PubMed ID: 30396050
[TBL] [Abstract][Full Text] [Related]
3. Determination of selpercatinib, a RET kinase inhibitor, in rat plasma and its application to a pharmacokinetic study.
Wang W; Shi L; Jin L; Wang K
Biomed Chromatogr; 2021 May; 35(5):e5052. PubMed ID: 33314236
[TBL] [Abstract][Full Text] [Related]
4. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
Wang Y; Sparidans RW; Potters S; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2021 Oct; 172():105850. PubMed ID: 34450308
[TBL] [Abstract][Full Text] [Related]
5. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.
Sparidans RW; Li W; Schinkel AH; Schellens JHM; Beijnen JH
J Pharm Biomed Anal; 2018 Nov; 161():136-143. PubMed ID: 30149189
[TBL] [Abstract][Full Text] [Related]
6. Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Retmana IA; Loos NHC; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1174():122718. PubMed ID: 33957355
[TBL] [Abstract][Full Text] [Related]
7. Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.
Li W; Perpinioti N; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122098. PubMed ID: 32278292
[TBL] [Abstract][Full Text] [Related]
8. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Dogan-Topal B; Li W; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Mar; 1110-1111():116-123. PubMed ID: 30802754
[TBL] [Abstract][Full Text] [Related]
9. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Sparidans RW; Tang SC; Nguyen LN; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():150-4. PubMed ID: 22940474
[TBL] [Abstract][Full Text] [Related]
10. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
11. Bioanalytical assay for the quantification of the tyrosine kinase inhibitor EAI045 and its major metabolite PIA in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Susam MM; Wang J; Schinkel AH; Beijnen JH; Sparidans RW
Biomed Chromatogr; 2022 Nov; 36(11):e5457. PubMed ID: 35855648
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
13. Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Sparidans RW; Li W; Schinkel AH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Aug; 1122-1123():78-82. PubMed ID: 31163324
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.
Martínez-Chávez A; Rosing H; Hillebrand M; Tibben M; Schinkel AH; Beijnen JH
Anal Bioanal Chem; 2019 Aug; 411(20):5331-5345. PubMed ID: 31209549
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma.
Gulikers JL; van Veelen AJ; Sinkiewicz EMJ; de Beer YM; Slikkerveer M; Stolk LML; Tjan-Heijnen VCG; Hendriks LEL; Croes S; van Geel RMJM
Biomed Chromatogr; 2023 Jun; 37(6):e5628. PubMed ID: 36941218
[TBL] [Abstract][Full Text] [Related]
16. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
[TBL] [Abstract][Full Text] [Related]
17. Determination of Pralsetinib in Human Plasma and Cerebrospinal Fluid for Therapeutic Drug Monitoring by Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS).
Zhao Z; Pu Q; Sun T; Huang Q; Tong L; Fan T; Kang J; Chen Y; Zhang Y
Anticancer Agents Med Chem; 2024 Apr; ():. PubMed ID: 38584556
[TBL] [Abstract][Full Text] [Related]
18. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
19. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium.
Martínez-Chávez A; Tibben MM; Broeders J; Rosing H; Schinkel AH; Beijnen JH
J Pharm Biomed Anal; 2020 Oct; 190():113516. PubMed ID: 32784092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
